Ironwood Pharmaceuticals (IRWD) Gains from Investment Securities (2015 - 2023)

Ironwood Pharmaceuticals (IRWD) has 9 years of Gains from Investment Securities data on file, last reported at -$19000.0 in Q1 2023.

• For the quarter ending Q1 2023, Gains from Investment Securities rose 95.44% year-over-year to -$19000.0; the trailing twelve-month figure through Dec 2023 stood at -$19000.0 (up 89.56% YoY), and the FY2023 full-year result was -$19000.0, up 89.56% from the prior year.
• Gains from Investment Securities eased to -$19000.0 in Q1 2023, from $1.1 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $15.5 million in Q4 2019 to a low of -$15.7 million in Q3 2019.
• A 5-year average of -$406647.1 and a median of -$151000.0 in 2022 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities jumped 998.63% in 2019 and slumped 314.28% in 2020, its largest moves.
• Tracing IRWD's Gains from Investment Securities over 5 years: stood at $15.5 million in 2019, then sank by 71.64% to $4.4 million in 2020, then slumped by 194.99% to -$4.2 million in 2021, then surged by 127.15% to $1.1 million in 2022, then plunged by 101.68% to -$19000.0 in 2023.
• Business Quant data shows IRWD's Gains from Investment Securities at -$19000.0 in Q1 2023, $1.1 million in Q4 2022, and -$151000.0 in Q3 2022.